Assessing the impact of exposome on the course of chronic obstructive pulmonary disease and cystc fibrosis: The REMEDIA European Project Approach.
Chronic ostructive pulmonary disease
Cystic fibrosis
Exposome
Journal
Environmental epidemiology (Philadelphia, Pa.)
ISSN: 2474-7882
Titre abrégé: Environ Epidemiol
Pays: United States
ID NLM: 101719527
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
07
09
2020
accepted:
28
06
2021
entrez:
20
8
2021
pubmed:
21
8
2021
medline:
21
8
2021
Statut:
epublish
Résumé
Because of the direct interaction of lungs with the environment, respiratory diseases are among the leading causes of environment-related deaths in the world. Chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) are two highly debilitating diseases that are of particular interest in the context of environmental studies; they both are characterized by a similar progressive loss of lung function with small bronchi alterations, and a high phenotypic variability of unknown origin, which prevents a good therapeutic efficacy. In the last years, there has been an evolution in the apprehension of the study of diseases going from a restricted "one exposure, one disease" approach to a broader concept with other associating factors, the exposome. The overall objective of the REMEDIA project is to extend the understanding of the contribution of the exposome to COPD and CF diseases. To achieve our aim, we will (1) exploit data from existing cohorts and population registries to create a unified global database gathering phenotype and exposome information; (2) develop a flexible individual sensor device combining environmental and biomarker toolkits; (3) use a versatile atmospheric simulation chamber to simulate the health effects of complex exposomes; (4) use machine learning supervised analyses and causal inference models to identify relevant risk factors; and (5) develop econometric and cost-effectiveness models to assess the costs, performance, and cost-effectiveness of a selection of prevention strategies. The results will be used to develop guidelines to better predict disease risks and constitute the elements of the REMEDIA toolbox. The multidisciplinary approach carried out by the REMEDIA European project should represent a major breakthrough in reducing the morbidity and mortality associated with COPD and CF diseases.
Identifiants
pubmed: 34414348
doi: 10.1097/EE9.0000000000000165
pmc: PMC8367060
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e165Subventions
Organisme : Medical Research Council
ID : G9815508
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_15018
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19009
Pays : United Kingdom
Informations de copyright
Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The Environmental Epidemiology. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest with regard to the content of this report.
Références
Eur Respir J. 2001 Jun;17(6):1201-7
pubmed: 11491165
Am J Respir Crit Care Med. 2003 May 15;167(10):1380-6
pubmed: 12522029
Int J Epidemiol. 2008 Feb;37(1):36-41
pubmed: 17644530
Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1847-50
pubmed: 16103423
F1000Res. 2017 May 19;6:726
pubmed: 28620467
Eur Respir J. 2019 Jul 18;54(1):
pubmed: 31000678
J Cyst Fibros. 2011 Jun;10 Suppl 2:S152-71
pubmed: 21658634
Clin Sci (Lond). 2014 Feb;126(3):207-21
pubmed: 23875733
Mediators Inflamm. 2018 Apr 8;2018:1309746
pubmed: 29849481
Expert Rev Respir Med. 2018 Jun;12(6):483-492
pubmed: 29750581
Int J Biochem Cell Biol. 2014 Jul;52:94-102
pubmed: 24631642